FOLH1 and neoplasm: <h4>Purpose</h4>To develop a dual-labeled PSMA-targeted tracer for radio- and fluorescence-guided surgery (RGS/FGS) with enhanced clinical utility due to optimized pharmacokinetics and tumor targeting.<h4>Methods</h4>Four novel hybrid PSMA ligands with varying cyanine-based fluorophores were comprehensively characterized preclinically.